摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(羟基甲基)喹唑啉-4(3H-)-酮 | 34637-40-6

中文名称
2-(羟基甲基)喹唑啉-4(3H-)-酮
中文别名
——
英文名称
2-(hydroxymethyl)quinazolin-4(3H)-one
英文别名
2-Hydroxymethyl-4(3H)-chinazolinon;2-(Hydroxymethyl)quinazolin-4(3h)-one;2-(hydroxymethyl)-3H-quinazolin-4-one
2-(羟基甲基)喹唑啉-4(3H-)-酮化学式
CAS
34637-40-6
化学式
C9H8N2O2
mdl
MFCD07339678
分子量
176.175
InChiKey
QXGGDTNBLBJSIJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.111
  • 拓扑面积:
    61.7
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933990090

SDS

SDS:54f7562a051af2937662a63b14751898
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(羟基甲基)喹唑啉-4(3H-)-酮四溴化碳三苯基膦 作用下, 以 二氯甲烷 为溶剂, 反应 22.0h, 以84%的产率得到2-(bromomethyl)-4(3H)-quinazolinone
    参考文献:
    名称:
    Chemical Probes to Study ADP-Ribosylation: Synthesis and Biochemical Evaluation of Inhibitors of the Human ADP-Ribosyltransferase ARTD3/PARP3
    摘要:
    The racemic 3-(4-oxo-3,4-dihydroquinazolin-2-yl)-N-[1-(pyridin-2-yl)ethyl]propanamide, 1, has previously been identified as a potent but unselective inhibitor of diphtheria toxin-like ADP-ribosyltransferase 3 (ARTD3). Herein we describe synthesis and evaluation of SS compounds in this class. It was found that the stereochemistry is of great importance for both selectivity and potency and that substituents on the phenyl ring resulted in poor solubility. Certain variations at the meso position were tolerated and caused a large shift in the binding pose. Changes to the ethylene linker that connects the quinazolinone to the amide were also investigated but proved detrimental to binding. By combination of synthetic organic chemistry and structure-based design, two selective inhibitors of ARTD3 were discovered.
    DOI:
    10.1021/jm401394u
  • 作为产物:
    参考文献:
    名称:
    Chemical Probes to Study ADP-Ribosylation: Synthesis and Biochemical Evaluation of Inhibitors of the Human ADP-Ribosyltransferase ARTD3/PARP3
    摘要:
    The racemic 3-(4-oxo-3,4-dihydroquinazolin-2-yl)-N-[1-(pyridin-2-yl)ethyl]propanamide, 1, has previously been identified as a potent but unselective inhibitor of diphtheria toxin-like ADP-ribosyltransferase 3 (ARTD3). Herein we describe synthesis and evaluation of SS compounds in this class. It was found that the stereochemistry is of great importance for both selectivity and potency and that substituents on the phenyl ring resulted in poor solubility. Certain variations at the meso position were tolerated and caused a large shift in the binding pose. Changes to the ethylene linker that connects the quinazolinone to the amide were also investigated but proved detrimental to binding. By combination of synthetic organic chemistry and structure-based design, two selective inhibitors of ARTD3 were discovered.
    DOI:
    10.1021/jm401394u
点击查看最新优质反应信息

文献信息

  • [EN] AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS CYCLIQUES AROMATIQUES AZOTÉS À 6 CHAÎNONS ET LEUR UTILISATION
    申请人:MITSUBISHI TANABE PHARMA CORP
    公开号:WO2010030027A1
    公开(公告)日:2010-03-18
    The present invention provides aromatic nitrogen-containing 6-membered ring compounds having execellent PDE10 inhibitory activity. The present invention relates to an aromatic nitrogen-containing 6-membered ring compound represented by the following formula [I0] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compounds for PDE10 inhibitors, and a pharmaceutical composition comprising said compounds as an active ingredient: Formula [I0] wherein: X1, X2 and X3 each independently are N or CH, and at least two of X1, X2 and X3 are N; A is *-CH=CH-, *-C(Alk)=CH-, *-CH2-CH2- or *-O-CH2- (* is a bond with R1); Alk is a lower alkyl group; Ring B is an optionally substituted nitrogen-containing aliphatic heterocyclic group; R1 is an optionally substituted nitrogen-containing heterocyclic group, a nitrogen-containing heterocyclic moiety of which is a moiety selected from the group consisting of quinoxalinyl, quinolyl, isoquinolyl, quinazolinyl, pyrazinyl, pyrimidinyl and a moiety thereof fused with a 5 to 6-membered aliphatic ring thereto; Y0 is a group selected from the group consisting of the following (1) to (5): (1) an optionally substituted phenyl or an optionally substituted aromatic monocyclic 5 to 6-membered heterocyclic group; (2) an optionally substituted aminocarbonyl; (3) an optionally substituted amino lower alkyl; (4) -O-R2 wherein R2 is hydrogen, an optionally substituted lower alkyl, lower cycloalkyl, aliphatic monocyclic 5 to 6-membered heterocyclic group, or Formula [AA]; (5) mono- or di-substituted amino; provided that, when Y0 is mono- or di-substituted amino, the nitrogen-containing heterocyclic moiety of R1 is not quinoxalinyl or quinolyl.
    本发明提供了具有出色的PDE10抑制活性的芳香氮含6元环化合物。本发明涉及以下式[I0]所代表的芳香氮含6元环化合物或其药学上可接受的盐,其制备方法,以及将所述化合物用作PDE10抑制剂,以及包含所述化合物作为活性成分的药物组合物:式[I0]其中:X1、X2和X3各自独立地为N或CH,并且至少两个X1、X2和X3为N;A为*-CH=CH-,*-C(Alk)=CH-,*-CH2-CH2-或*-O-CH2-(*为与R1的键);Alk为低碳烷基基团;环B为可选择取代的含氮脂肪杂环基团;R1为可选择取代的含氮杂环基团,其中的氮杂环基团为从喹喔啉基,喹啉基,异喹啉基,喹唑啉基,吡嗪基,嘧啶基中选取的基团,或者与其中的5至6元脂环融合的基团;Y0为从以下(1)到(5)组成的基团:(1)可选择取代的苯基或可选择取代的芳香单环5至6元杂环基团;(2)可选择取代的氨基羰基;(3)可选择取代的氨基低碳烷基;(4)-O-R2其中R2为氢,可选择取代的低碳烷基,低环烷基,脂肪单环5至6元杂环基团,或式[AA];(5)单取代或双取代氨基;但是,当Y0为单取代或双取代氨基时,R1的含氮杂环基团不是喹喔啉基或喹啉基。
  • Synthesis of Chrysogine, a Metabolite of Penicillium chrysogenum and some related 2-substituted 4-(3H)-Quinazolinones
    作者:Jan Bergman、Anna Brynolf
    DOI:10.1016/s0040-4020(01)86694-1
    日期:1990.1
    Syntheses of both enantiomers of chrysogine, 2-(α-hydroxyethyl)-4(3H)-quinazolinone, 1 from 2-ammobenzamide are reported. Thus reaction of 2-aminobenzamide and optically active α-acetoxypropionyl chloride gave 9, which upon saponification and cyclization induced by aqueous sodium carbonate at room temperature gave chrysogine. The enantiomeric purity of 1 was determined by NMR. Inversion of (-)-(S)-1
    据报道,由2-氨苯甲酰胺合成了金葡胺的两种对映体2-(α-羟乙基)-4(3H)-喹唑啉酮1。因此,2-氨基苯甲酰胺与旋光性α-乙酰氧基丙酰氯的反应得到9,其在室温下由碳酸钠水溶液诱导的皂化和环化后得到金柳胺。通过NMR确定1的对映体纯度。使用Mitsunobo反应将(-)-(S)-1转化,得到(+)-(R)-1。的还原2 -乙酰基-4(3H)-qumazolinone 2与面包酵母,得到的S-对映体1。可以扩展使用的环化方法,并且还报道了许多2-(α-羟基)烷基-4-(3H)-喹唑啉酮。
  • [EN] METHODS FOR TREATING VIRAL INFECTIONS<br/>[FR] MÉTHODES DE TRAITEMENT DES INFECTIONS VIRALES
    申请人:CALIFORNIA INST BIOMEDICAL RES
    公开号:WO2016161176A1
    公开(公告)日:2016-10-06
    Described herein are methods for treating a viral infection comprising administering to an individual in need thereof a therapeutically effective amount of a compound of Formula I: Formula (I).
    本文描述了治疗病毒感染的方法,包括向需要治疗的个体施用化合物I的治疗有效量:公式(I)。
  • A General Synthetic Procedure for 2-chloromethyl-4(3H)-quinazolinone Derivatives and Their Utilization in the Preparation of Novel Anticancer Agents with 4-Anilinoquinazoline Scaffolds
    作者:Hong-Ze Li、Hai-Yun He、Yuan-Yuan Han、Xin Gu、Lin He、Qing-Rong Qi、Ying-Lan Zhao、Li Yang
    DOI:10.3390/molecules15129473
    日期:——
    series of novel 2-chloromethyl-4(3H)-quinazolinones were needed as key intermediates. An improved one-step synthesis of 2-chloromethyl-4(3H)-quinazolinones utilizing o-anthranilic acids as starting materials was described. Based on it, 2-hydroxy-methyl-4(3H)-quinazolinones were conveniently prepared in one pot. Moreover, two novel 4-anilinoquinazoline derivatives substituted with chloromethyl groups at
    在我们正在进行的具有 4-苯胺基喹唑啉支架的新型抗癌剂的研究中,需要一系列新型 2-氯甲基-4(3H)-喹唑啉酮作为关键中间体。描述了使用邻氨基苯甲酸作为起始材料的 2-氯甲基-4(3H)-喹唑啉酮的改进一步合成。在此基础上,2-羟基-甲基-4(3H)-喹唑啉酮方便地在一锅中制备。此外,合成了两种在 2 位被氯甲基取代的新型 4-苯胺基喹唑啉衍生物,并在体外显示出良好的抗癌活性。
  • AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE
    申请人:Morimoto Hiroshi
    公开号:US20110166135A1
    公开(公告)日:2011-07-07
    The present invention provides aromatic nitrogen-containing 6-membered ring compounds having excellent PDE10 inhibitory activity. The present invention relates to an aromatic nitrogen-containing 6-membered ring compound represented by the following formula [I 0 ] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compounds for PDE10 inhibitors, and a pharmaceutical composition comprising said compounds as an active ingredient: Formula [I 0 ] wherein: X 1 , X 2 and X 3 each independently are N or CH, and at least two of X 1 , X 2 and X 3 are N; A is *—CH═CH—, *—C(Alk)=CH—, *—CH 2 —CH 2 — or *—O—CH 2 — (* is a bond with R 1 ); Alk is a lower alkyl group; Ring B is an optionally substituted nitrogen-containing aliphatic heterocyclic group; R 1 is an optionally substituted nitrogen-containing heterocyclic group, a nitrogen-containing heterocyclic moiety of which is a moiety selected from the group consisting of quinoxalinyl, quinolyl, isoquinolyl, quinazolinyl, pyrazinyl, pyrimidinyl and a moiety thereof fused with a 5 to 6-membered aliphatic ring thereto; Y 0 is a group selected from the group consisting of the following (1) to (5): (1) an optionally substituted phenyl or an optionally substituted aromatic monocyclic 5 to 6-membered heterocyclic group; (2) an optionally substituted aminocarbonyl; (3) an optionally substituted amino lower alkyl; (4) —O—R 2 wherein R 2 is hydrogen, an optionally substituted lower alkyl, lower cycloalkyl, aliphatic monocyclic 5 to 6-membered heterocyclic group, or Formula [AA]; (5) mono- or di-substituted amino; provided that, when Y 0 is mono- or di-substituted amino, the nitrogen-containing heterocyclic moiety of R 1 is not quinoxalinyl or quinolyl.
    本发明提供了具有优异的PDE10抑制活性的芳香族含氮6元环化合物。本发明涉及以下式[I0]或其药学上可接受的盐,其为一种芳香族含氮6元环化合物,以及其制备方法,用于PDE10抑制剂的化合物和包含该化合物作为活性成分的药物组合物:式[I0]其中:X1、X2和X3各自独立地为N或CH,且至少两个X1、X2和X3为N;A为*—CH═CH—、*—C(Alk)=CH—、*—CH2—CH2—或*—O—CH2—(*为R1的键);Alk为低碳基;环B为可选取代的含氮脂肪族杂环基;R1为可选取代的含氮杂环基,其中含氮杂环基是从喹啉基、喹啉基、异喹啉基、喹唑啉基、吡嗪基、嘧啶基和它们与5至6元脂环环融合的基中选择的基;Y0为从以下组合中选择的基(1)到(5):(1)可选取代的苯基或可选取代的芳香单环5至6元杂环基;(2)可选取代的氨基甲酰基;(3)可选取代的氨基低碳基;(4)—O—R2,其中R2为氢、可选取代的低碳基、低环烷基、脂肪单环5至6元杂环基或式[AA];(5)单取代或双取代的氨基;但当Y0为单取代或双取代的氨基时,R1的含氮杂环基不是喹啉基或喹啉基。
查看更多